OUTLOOK THERAPEUTICS INC (OTLK) Earnings History & Surprises

NASDAQ:OTLK • US69012T3059

0.43 USD
0 (0%)
Last: Mar 12, 2026, 01:45 PM

Past quarterly earnings results for OUTLOOK THERAPEUTICS INC (OTLK), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).

Earnings Snapshot

Next Earnings Date

Upcoming
Release DateMay 13, 2026
PeriodQ2 / 2026
EPS Estimate-$0.17
Revenue Estimate5.066M

Last Reported

Most Recent
Release DateFeb 17, 2026
PeriodQ1 / 2026
EPS Reported-$0.22
EPS Surprise -19.83%
Revenue Surprise -123.57%

Beat Rate

Last 8 Quarters
31%
EPS and Revenuebeats vs estimates

Quarterly Earnings Results

EPS & Revenue History (USD)

Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.

QuarterEPSEPS EstEPS SurpriseEPS Q2QRevenueRevenue EstRevenue SurpriseRevenue Q2Q
Q1 2026 -0.22 -0.18 -19.83% -130.56% -1.208M 5.126M -123.57% -
Q4 2025 -0.19 -0.26 26.47% -125.00% -92K 5.967M -101.54% -
Q3 2025 -0.55 -0.40 -37.09% 33.73% 1.505M 1.696M -11.26% -
Q2 2025 -0.40 -0.61 34.42% 74.19% 716.652K -100.00% -
Q1 2025 0.72 -0.79 191.08% 190.00% - -
Q4 2024 0.76 -0.85 189.34% 176.00% - -
Q3 2024 -0.83 -1.02 18.46% 48.13% - -
Q2 2024 -1.55 -0.87 -78.78% -158.33% - -
Q1 2024 -0.80 -1.02 21.57% 50.00% - -
Q4 2023 -1.00 -1.20 16.56% 23.08% 179.775K -100.00% -
Q3 2023 -1.60 -1.05 -52.50% - - -
Q2 2023 -0.60 -1.33 54.75% 66.67% - -
Q1 2023 -1.60 -1.07 -49.39% - - -
Q4 2022 -1.30 -1.38 5.59% 27.78% - -
Q3 2022 -1.60 -1.53 -4.58% -14.29% - -
Q2 2022 -1.80 -1.29 -39.33% - - -
Q1 2022 -1.60 -1.22 -30.72% 33.33% - -
Q4 2021 -1.80 -1.22 -47.06% 30.77% 306K -100.00% -
Q3 2021 -1.40 -1.50 6.41% 36.36% 331.5K -100.00% -
Q2 2021 -1.80 -1.63 -10.29% 30.77% 331.5K -100.00% -
Q1 2021 -2.40 -1.63 -47.06% 57.14% - -
Q4 2020 -2.60 -1.63 -59.31% - 132.6K -100.00% -
Q3 2020 -2.20 -2.24 1.96% - 165.75K -100.00% -
Q2 2020 -2.60 -3.16 17.77% - 132.6K -100.00% -
Q1 2020 -5.60 -5.03 -11.29% - 446.25K -100.00% -

Notes

  • EPS and Revenue values are non-GAAP when available, otherwise GAAP.
  • Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
  • Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
  • Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.

Earnings Q2Q Performance Trends

EPS Historical Q2Q growth and Acceleration

OTLK EPS Q2Q GrowthOTLK EPS Q2Q GrowthEPS Q2Q Growth Q1/21 Q3/21 Q1/22 Q3/22 Q1/23 Q3/23 Q1/24 Q3/24 Q1/25 Q3/25 Q1/26 Q3/26 Q1/27 Q3/27 0 100 -100

Revenue Historical Q2Q growth and Acceleration

OTLK Revenue Q2Q GrowthOTLK Revenue Q2Q GrowthRevenue Q2Q Growth Q3/26 Q4/26 Q1/27 Q2/27 Q3/27 Q4/27 0 2K 4K 6K 8K 10K

Surprise distribution (Last 4 Quarters)

EPS beat statistics

EPS beat (4)
2
Average EPS beat (4)
0.99%
Max EPS beat (4)
34.42%
Min EPS beat (4)
-37.09%

Revenue beat statistics

Revenue beat (4)
0
Average Revenue beat (4)
-84.09%
Max Revenue beat (4)
-11.26%
Min Revenue beat (4)
-123.57%

Analysis

In the last 4 quarters, OTLK has beaten EPS estimates in 2 out of 4 releases
OTLK has not beaten revenue estimates in any of the last 4 earnings releases
In the last 4 quarters, OTLK has beaten the EPS estimates by 1.0% on average.
In the last 4 quarters, OTLK reported -84.1% below the revenue estimates on average.
→ Find peers who consistently beat earnings by at least 10% in the last 4 quarters

OUTLOOK THERAPEUTICS INC / OTLK Earnings FAQ

When did OUTLOOK THERAPEUTICS INC (OTLK) report earnings last quarter?

OUTLOOK THERAPEUTICS INC (OTLK) last reported earnings on 2/17/2026.


Can you provide information on whether OUTLOOK THERAPEUTICS INC beat earnings estimates in the last quarter?

OUTLOOK THERAPEUTICS INC (OTLK) missed EPS estimates and missed revenue estimates in the most recent quarter.


How often does OUTLOOK THERAPEUTICS INC (OTLK) beat earnings estimates?

In the last 4 quarters, OUTLOOK THERAPEUTICS INC (OTLK) has beaten EPS estimates in 2 out of 4 releases.